Rezolute, Inc. (RZLT) Stock Price & Analysis
Rezolute, Inc. (RZLT) rose 0.88% to USD 4.58 as of September 8, 2026 at 12:45 UTC, according to Nexqual real-time market data.
RZLT last closed at USD 4.58; the session ranged USD 4.44–4.62 on volume of 716,948 shares. Market capitalization is —, with a 52-week range of USD 1.07–11.46 (NCM). Source: Nexqual, September 8, 2026 at 12:45 UTC.
Key Statistics (as of September 8, 2026 at 12:45 UTC)
| Price | USD 4.58 |
|---|---|
| Change | ▲ 0.88% (up) |
| Previous Close | USD 4.58 |
| Open | USD 4.58 |
| Day Range | USD 4.44 – 4.62 |
| 52-Week Range | USD 1.07 – 11.46 |
| Volume | 716,948 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (RZLT)
Nexqual's technical model rates RZLT "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.06 (neutral) |
| vs SMA50 | Below (USD 4.81) |
| MACD | -0.04 (negative) |
From Rezolute, Inc.'s Latest SEC 10-K Filing (filed 2025-09-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Research and Development We incurred approximately $61.5 million and $55.7 million in research and development expenses for the fiscal years ended June 30, 2025 and 2024, respectively.
- We believe that a rich culture of inclusion and diversity enables us to create, develop and fully leverage the strengths of our workforce.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LRMR | Larimar Therapeutics, Inc. | USD 3.83 | ▼ 1.03% |
| ELDN | Eledon Pharmaceuticals, Inc. | USD 3.02 | ▲ 1% |
| TRVI | Trevi Therapeutics, Inc. | USD 17.26 | ▲ 1.23% |
| TARA | Protara Therapeutics, Inc. | USD 3.94 | ▲ 0% |
| JSPR | Jasper Therapeutics, Inc. | USD 0.71 | ▲ 0.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:45 UTC. This page is informational and not investment advice.